Determining menopausal status is important to all women
Menopausal transition is the period when the hormones produced by ageing ovaries fluctuate leading to irregular menstrual patterns.
The loss of hormones from the ovary has profound effects on woman’s quality of life (hot flashes, mood changes, night sweating etc.) and her risk for diseases (bone loss, bone fracture cognitive decline, etc. ) during menopausal transition.
Each women at the specific age are at different stage of menopause: pre, peri and post menopause. Knowing the menopausal status and approximately how long she personally will have to endure symptoms can help personalize decision making with her physician.
Furthermore, estimating the relative level of her fertility by assessing her personal menopausal status allows a woman to make personalized decisions regarding contraception during the transition to menopause and complete infertility.
Meno√Check® supports physician to manage women in need
Meno√Check is a unique blood test for the measurement of Anti-Mullerian Hormone (AMH) in serum. It is manufactured by Ansh Labs LLC and is the only FDA cleared method for measuring AMH for the determination of menopausal status.
Meno√Check is the only commercially available test that has the sensitivity to detect ultra-low levels of AMH. The data supporting the use of the Meno√Check test was acquired from over 1500 women participating in a 20-year study, involving careful clinical observations and hormone measurements annually, as they underwent the menopausal transition and 12 months of amenorrhea to allow an accurate FMP date.
Excerpts from U.S. News and World Report’s article titled, “Great Breakthroughs for Menopause Management“
In particular, “women who have heavy menstrual bleeding and want to avoid having a hysterectomy might benefit from knowing that the bleeding won’t last much longer.” “On the other hand, if they have a high AMH and they know they are looking at five or more years of bothersome symptoms, they may feel more comfortable choosing a more aggressive option.” The test results could help other women decide whether they should invest in another five-year IUD or contraceptive implant if they’re looking for long-acting contraception.
Dr. Nanette Santoro, MD
Stewart Taylor Chair and Professor of Obstetrics and Gynecology, University of Colorado School of Medicine
“Early menopause, whether it’s spontaneous or due to surgery or medications such as chemotherapy, is associated with a higher risk of osteoporosis and fracture, heart diseases, cognitive changes, vaginal changes, loss of libido and mood changes.”
“If it’s discovered that a woman is likely to have early menopause, she should be advised to take adequate calcium and vitamin D (1,200 mg and 1,000 to 2,000 IU daily, respectively), keep her weight down with a healthy diet and regular exercise and be evaluated for risk for bone loss.
When it comes to preventing heart disease, recommendations should include regular cardio exercises and strength-training workouts, eating fiber-rich foods and lots of vegetables and fruits, avoiding fried and sugary foods, reducing calorie intake and managing other cardiovascular risk factors (such as high blood pressure, blood sugar and cholesterol levels).”
Dr. JoAnn Pinkerton, MD
Executive Director, North American Menopause Society
Professor, Obstetrics and Gynecology at the University of Virginia, Charlottesville.
Excerpts from an Endocrine News’ article titled, “Predicting Menopause: A New Test Could Improve Accuracy“. See Page 30
The past century has brought us some incredible medical marvels…and with these advances, human life expectancy has increased. [A] longer lifespan means an increased risk of problems like cancer and dementia…..[and] an increase in the duration of a woman’s postmenopausal life. Women now live for approximately 30 years after their final menstrual period (FMP), compared with just two years in the early 1900s.”
“Establishing a way to measure time to the final menstrual period has long been the holy grail of menopause research,” she continues. “Women can make better medical decisions with the more complete information offered by new, more sensitive anti-Müllerian hormone measurements.”
Excerpts from FDA’s Press Release titled, “FDA permits marketing of a diagnostic test to aid in the determination of menopausal status“
“Diagnostic results about a woman’s menopausal status may prompt discussions about preventative care for women experiencing menopausal symptoms,” “This test, when used in conjunction with other clinical assessments and laboratory findings, can help inform discussions about preventative care, such as ways to help prevent loss in bone mineral density or to address cardiovascular disease, both of which are known to increase after menopause.”
Dr. Courtney Lias, Ph.D.
Director of the Division of Chemistry and Toxicology Devices
FDA Center for Devices and Radiological Health
How to get tested with MenoCheck
More and more laboratories are offering the MenoCheck test. In case your physician is not aware of MenoCheck, print out this flyer and hand it to them so they have a point of contact. Also, most physicians have hospital privileges and the laboratories in those hospitals can either run the test or send the samples to our CLIA-certified clinical laboratory.